Healthcare & Pharmaceuticals

Inovio expands partnership with Advaccine for COVID-19 vaccine study

2 minute read

A woman holds a small bottle labelled with a "Coronavirus COVID-19 Vaccine" sticker and a medical syringe in this illustration taken October 30, 2020. REUTERS/Dado Ruvic

Register now for FREE unlimited access to

June 8 (Reuters) - Inovio Pharmaceuticals Inc (INO.O) on Tuesday expanded its partnership with Advaccine Biopharmaceuticals to conduct a late-stage trial of its COVID-19 vaccine candidate, expected to start in the summer.

Inovio and Advaccine had entered into an agreement in January, under which Advaccine gained the exclusive right to develop and market the DNA vaccine, INO-4800, within Greater China.

Under the expanded deal, the companies expect to equally share the total cost of the late-stage trial, expected to be about $100 million, Inovio said.

Register now for FREE unlimited access to

Advaccine will also get rights to additional Asian countries outside of Greater China.

Inovio has fallen behind rivals in the race to develop a COVID-19 vaccine after the U.S. health regulator last year put the Phase 3 portion of its mid-to-late stage trial on hold for more information on the device used to deliver the vaccine candidate into skin cells.

The company said the potential vaccine, INO-4800, will be tested among those who are 18 years and older across several countries, mainly in Latin America and Asia.

Register now for FREE unlimited access to
Reporting by Amruta Khandekar; Editing by Arun Koyyur

Our Standards: The Thomson Reuters Trust Principles.

More from Reuters